GREEN BAY, WI (September 4th, 2012)—Leading supplement manufacturer, Integrative Therapeutics, has launched Pro-Flora Women's Probiotic: a clinically-proven Lactobacillus GR-1® and RC-14® combination.
Dr. Tori Hudson, ND, Program Director for the Institute of Women's Health and Integrative Medicine, emphasizes the need for condition-specific probiotic supplementation for women, "Vaginal health concerns are one of the leading reasons women visit healthcare practitioners, and balancing vaginal microflora is essential for maintaining vaginal health. Using a probiotic designed and clinically-studied for treating flora imbalances in the vaginal tract is extremely important."
Pro-Flora Women's Probiotic is a combination of two proprietary, clinically-proven Lactobacillus strains, Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14, that are supported by more than 20 years of clinical research in supporting urogenital health.*1-3
A randomized, placebo-controlled clinical trial demonstrated vaginal colonization following oral administration to 64 healthy women. Participants took a capsule containing GR-1 and RC-14, or a matching placebo, once per day for 60 days. The combination was found to significantly and beneficially alter the vaginal flora.* Culture findings confirmed a significant increase in Lactobacilli at day 28 and day 60.* At day 28, individuals who received GR-1 and RC-14 demonstrated improved yeast balance.*1
This combination is also safe to use with pregnant women, and can be used with conventional options for urogenital health.*2
For more information on the clinically-studied probiotic strains in Pro-Flora Women's Probiotic, visit www.IntegrativeInc.com.
Integrative Therapeutics, LLC manufactures and distributes proprietary, natural supplements exclusively to medical professionals. Our manufacturing facility meets stringent quality standards and is an organically certified and drug GMP audited facility. Find out more at www.IntegrativeInc.com.
- Reid G, Charbonneau D, Erb J, et al. Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. FEMS Immunol Med Microbiol 2003;35:131–4.
- Anukam KC, Osazuwa E, Ahonkhai I, et al. Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial. Microbes Infect 2006;8:1450–4.
- McMillan A, Dell M, Zellar MP, et al. Disruption of urogenital biofilms by lactobacilli. Colloids Surf B Biointerfaces 2011;86:58–64.
*This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.